Pathwork Diagnostics, Novartis Team Up for Cancer Biomarker Discovery | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics developer Pathwork Diagnostics announced today a collaboration with Novartis for the discovery of cancer biomarkers.

The biomarkers will be used as a basis for diagnostics "across a range of cancer types," the Redwood City, Calif.-based firm said in a statement.

Under the terms of the deal, both companies have the rights to develop and commercialize the diagnostic products. Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.